MXPA04001959A - Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. - Google Patents

Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Info

Publication number
MXPA04001959A
MXPA04001959A MXPA04001959A MXPA04001959A MXPA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A
Authority
MX
Mexico
Prior art keywords
dementia
galantamine
formula
topiramate
resulting
Prior art date
Application number
MXPA04001959A
Other languages
English (en)
Spanish (es)
Inventor
Plata-Salaman Carlos
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA04001959A publication Critical patent/MXPA04001959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04001959A 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. MXPA04001959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31597801P 2001-08-30 2001-08-30
PCT/US2002/027504 WO2003020289A1 (en) 2001-08-30 2002-08-28 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MXPA04001959A true MXPA04001959A (es) 2005-02-17

Family

ID=23226936

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001959A MXPA04001959A (es) 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Country Status (6)

Country Link
US (1) US20030060423A1 (OSRAM)
EP (1) EP1423127A1 (OSRAM)
JP (1) JP2005502680A (OSRAM)
CA (1) CA2459146A1 (OSRAM)
MX (1) MXPA04001959A (OSRAM)
WO (1) WO2003020289A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
AU2004317129A1 (en) * 2004-03-12 2005-09-22 Egis Gyogyszergyar Nyrt. Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
CN101588802A (zh) * 2006-12-01 2009-11-25 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
JP5421252B2 (ja) * 2008-05-30 2014-02-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 経皮吸収製剤
CA2724502A1 (en) * 2008-05-30 2009-12-03 Nitto Denko Corporation Adhesive preparation containing donepezil, and package of the same
US20110207718A1 (en) * 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
WO1998000124A1 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
WO2000032183A1 (en) * 1998-12-03 2000-06-08 Ortho-Mcneil Pharmaceutical, Inc. Topiramate and related derivatives for treating schizophrenia
CA2369095C (en) * 1999-04-08 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
MXPA01012187A (es) * 1999-05-28 2002-06-21 Jeffrey Berlant Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
DK1311272T3 (da) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
JP2004505043A (ja) * 2000-08-02 2004-02-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド うつ病の治療で用いるに有用な抗痙攣性誘導体
US6908902B2 (en) * 2001-02-02 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability

Also Published As

Publication number Publication date
WO2003020289A9 (en) 2003-07-10
CA2459146A1 (en) 2003-03-13
JP2005502680A (ja) 2005-01-27
US20030060423A1 (en) 2003-03-27
WO2003020289A1 (en) 2003-03-13
EP1423127A1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
MXPA04001959A (es) Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.
US9750746B2 (en) ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
AU782344B2 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
EP1309325A1 (en) Anticonvulsant derivatives useful for the treatment of depression
BG106708A (bg) Пиролидинацетамидни производни самостоятелно или в комбинация за лечение на разстройства на цнс
AU2007313911A1 (en) Treatment of Pervasive Developmental Disorders
EP2288345A1 (en) Psycho-pharmaceuticals
MXPA04008259A (es) Co-terapia para el tratamiento de migrana que comprende derivados de un anticonvulsivo y agentes anti-migrana.
CA2556969A1 (en) Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US6486198B1 (en) Compounds and methods for the treatment of post traumatic stress disorder
US20050090488A1 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
AU2003226753B2 (en) Statin therapy for enhancing cognitive maintenance
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005508373A (ja) 抗痙攣剤誘導体およびカリウムを用いる共同療法を含んでなる感覚異常の処置および予防
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
KR20230163367A (ko) 실행 기능 장애를 치료하기 위한 조합 요법
Hazekamp et al. Clinical Studies With Cannabis and Cannabinoids, 2005-2009
MXPA06009838A (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
MXPA99003258A (en) Anticonvulsant derivatives useful in treating neuropathic pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal